Our interpretation is that FABP4, at least at present, is not a “stand alone” biomarker which can be used clinically to identify patients at risk, but our findings suggest that studying circulating FABP4 in larger stroke populations could be of interest. The gene discussed is FABP4; the disease is Stroke.